Anti-IL17A/IL-17F Antibody (Bimekizumab)
Catalog No.
F2096
Anti-IL17A/IL-17F Antibody (Bimekizumab)
Featured Products
Bimekizumab is a monoclonal antibody that targets interleukin (IL)-17A and IL-17F, cytokines involved in the inflammatory process. It was developed by UCB, a global biopharmaceutical company. Bimekizumab consists of a humanized IgG1 monoclonal antibody. Its mechanism of action involves dual inhibition of IL-17A and IL-17F, which helps reduce inflammation and modulate the immune response. It is primarily used to treat moderate to severe plaque psoriasis and is being studied for other inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis.
Dry ice
1418205-77-2
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
UCB4940, BIMZELX
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
IL17A/IL-17F
Please avoid freeze-thaw cycles.